Medindia

X

Advanced Life Sciences Applies to IRS for Cash Grant Under the Qualifying Therapeutic Discovery Project

Tuesday, August 3, 2010 Research News J E 4
Advertisement

CHICAGO, Aug. 3 /PRNewswire-FirstCall/ -- Advanced Life Sciences Holdings, Inc. (OTC Bulletin Board: ADLS), a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, oncology and respiratory diseases, today announced that the Company has applied for a cash grant under the Qualifying Therapeutic Discovery Project which was created by Congress as part of the Patient Protection and Affordable Care Act of 2010. The Company has submitted an application for its development of Restanza™, a novel once-daily oral antibiotic for the treatment of community acquired bacterial pneumonia (CABP).

(Logo: http://photos.prnewswire.com/prnh/20080218/ALSLOGO)

(Logo: http://www.newscom.com/cgi-bin/prnh/20080218/ALSLOGO)

To be eligible, a project must: (i) have the potential to develop new treatments that address "unmet medical needs" or chronic and acute diseases; (ii) reduce long-term health care costs; (iii) represent a significant advance in finding a cure for cancer; (iv) advance U.S. competitiveness in the fields of life, biological, and medical sciences; or (v) create or sustain well-paying jobs, either directly or indirectly.  Total funds available under the program are limited to $1 billion, with a limitation on grants equal to $5 million per company.

"We are excited about the opportunity to be awarded a significant cash grant that will assist us in moving the Restanza program forward," said John L. Flavin, President and CFO of Advanced Life Sciences.  "We believe we have submitted a quality application and project information memorandum that will meet the requirements necessary for a successful outcome."

The deadline for the Internal Revenue Service to issue certification letters to taxpayers is October 29, 2010 and in conjunction, the U.S. Treasury will also begin to pay grants for 2009 qualified investments.  Grant payments for 2010 qualified investments are expected to be made by January 31, 2011.

About Advanced Life Sciences

Advanced Life Sciences is a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, cancer and respiratory diseases. The Company's lead candidate, Restanza, is a novel once-a-day oral antibiotic in late-stage development for the treatment of respiratory tract infections including CABP and biodefense pathogens including anthrax, plague and tularemia. For more information, please visit us on the web at www.advancedlifesciences.com or follow us on twitter at http://twitter.com/advancedlifesci.

Forward-Looking Statements

Any statements contained in this press release that relate to future plans, events or performance are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.  Forward-looking statements represent our management's judgment regarding future events.  The Company does not undertake any obligations to update any forward-looking statements whether as a result of new information, future events or otherwise.  Our actual results could differ materially from those discussed herein due to several factors including the success and timing of our clinical trials and our ability to obtain and maintain regulatory approval and labeling of our product candidates; our plans to develop and commercialize our product candidates; the loss of key scientific or management personnel; the size and growth of potential markets for our product candidates and our ability to serve those markets; regulatory developments in the U.S. and foreign countries; the rate and degree of market acceptance of any future products; the accuracy of our estimates regarding expenses, future revenues and capital requirements; our ability to obtain financing on terms acceptable to us; our ability to obtain and maintain intellectual property protection for our product candidates; the successful development of our sales and marketing capabilities; the success of competing drugs that become available; and the performance of third party collaborators and manufacturers.  These and additional risks and uncertainties are detailed in the Company's filings with the Securities and Exchange Commission.

SOURCE Advanced Life Sciences Holdings, Inc.

Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
China Pharma Holdings, Inc. to Report Second Quart...
S
Save the Date: Centene Corporation Announces 2011 ...